Ubs Group Ag Can Fite Bio Pharma Ltd. Transaction History

Ubs Group Ag

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 08, 2023	SELL	$0.6 - $8.94 $5,190 - $77,331	-8,650 Reduced 49.82%	8,712 $5,000
Q3 2022 Nov 10, 2022	BUY	$0.74 - $7.9 $7,282 - $77,743	9,841 Added 130.85%	17,362 $13,000
Q2 2022 Aug 10, 2022	BUY	$0.83 - $1.24 $282 - $421	340 Added 4.73%	7,521 $7,000
Q1 2022 May 16, 2022	BUY	$0.94 - $1.45 $6,750 - $10,412	7,181 New	7,181 $9,000
Q3 2021 Nov 15, 2021	SELL	$1.65 - $2.34 $12,719 - $18,039	-7,709 Closed	0 $0
Q2 2021 Aug 13, 2021	BUY	$1.97 - $2.48 $15,186 - $19,118	7,709 New	7,709 $18,000
Q3 2020 Nov 12, 2020	SELL	$1.61 - $2.67 $4,929 - $8,175	-3,062 Closed	0 $0
Q2 2020 Jul 31, 2020	SELL	$1.28 - $2.5 $7,074 - $13,817	-5,527 Reduced 64.35%	3,062 $6,000
Q1 2020 May 01, 2020	BUY	$1.13 - $3.52 $8,856 - $27,589	7,838 Added 1043.68%	8,589 $11,000
Q4 2019 Feb 14, 2020	BUY	$1.95 - $4.4 $1,464 - $3,304	751 New	751 $2,000

1.1K

Ticker CANF
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 27,191,500
Market Cap $54.7M
Description
Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction. The company's lead drug candidate Piclidenoson, which has been completed Phase III clinical trial for the treatment of psoriasis; and Phase II clinic...

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

Stay updated on Ubs Group Ag with notifications on news.